1.A Study for GnRH Antagonist (Cetrotide) Short Protocol in Controlled Ovarian Hyperstimulation.
Moon Young KIM ; Byeong Jun JUNG
Korean Journal of Fertility and Sterility 2001;28(4):265-270
OBJETIVE: The aim of this study was to evaluate the outcome the GnRH antagonist (Cetrotide) short protocol in controlled ovarian hyperstimulation comparing with GnRH agonist long protocol. MATERIALS AND METHOD: From July 2000 to November 2001, 26 patients, 28 cycles were performed in controlled ovarian hyperstimulation by GnRH antagonist and GnRH agonist. GnRH antagonist (Cetrotide) was administered in 12 patients (14 cycles, Group 1) and GnRH agonist (Lucrin, Sub Q, Group 2) in 14 patients (14 cycles). Ovulation induction was performed by hMG (Pergonal) in group 1, and by Combo (Metrodine HP + Pergonal) in group 2. We compared the fertilization rate, good quality embryo, and clinical pregnancy rate between the two groups. Student-t test and Chi-square were used to determine statistical significance. Statistical significance was defined as p<0.05. RESULTS: Ovarian hyperstimulation syndrome did not occurred in which estradiol (E2) level was 3874+/-809 pg/ml and the number of retrieved oocytes was 18.4+/-2.4. The number of used gonadotropin ampules was significantly decreased in Group 1 (26.0 vs. 33.1, p<0.04). There were no significant difference in the number of preovulatory oocyte (10.6+/-6.9 vs. 10.0+/-6.1), fertilization rate (74.8+/-23.4 vs. 72.2+/-21.8), good quality embryo (58.7+/-23.6 vs. 38.7+/-36.6), and embryo transfer (4.3+/-1.6 vs. 4.4+/-1.6). Although the age of the group 1 was older than the group 2 (34.4 vs. 30.8), there was no significant difference in clinical pregnancy rate (50.0% vs. 57.1%). CONCLUSIONS: We suggest that GnRH antagonist was a safe, effective, and alternative method in the controlled ovarian hyperstimulation, especially in PCOD patients who will be develop the ovarian hyperstimulation syndrome.
Embryo Transfer
;
Embryonic Structures
;
Estradiol
;
Female
;
Fertilization
;
Gonadotropin-Releasing Hormone*
;
Gonadotropins
;
Humans
;
Oocytes
;
Ovarian Hyperstimulation Syndrome
;
Ovulation Induction
;
Pregnancy Rate
2.Significance of colonoscopy in intestinal tuberculosis.
Won Jun CHOI ; Hong Young MOON ; Bum Hwan KOO
Journal of the Korean Surgical Society 1992;42(3):304-312
No abstract available.
Colonoscopy*
;
Tuberculosis*
3.Analysis of positive patch tests of fragrance allergy.
Jun Young KIM ; Kee Chan MOON ; Soo Nam KIM
Korean Journal of Dermatology 1992;30(1):57-61
63 of 348 patients patch tested with an European standard series, had positive reaction to either a fragrance mix or Balsam of Peru. Twelve showed positiv reaction to bot,h patches. The number of positive patch tests to the fragrance mix was 56, while those to Balsarn of Peru was 19 out, of the 63 patients, manifesting sensitivities of 83% and 30% repectively. The fragrance mix was considered a useful screening patch for fragrance allergies. Twenty-five of the patients showing fragrance allergy were further analysed with 8 individual fragrance ingredients at 2% petrolatum. Cinnamic aldehyde and cinnamic alcohol were considered as she most frequent and important. sensitizers.
Humans
;
Hypersensitivity*
;
Mass Screening
;
Patch Tests*
;
Peru
;
Petrolatum
4.Pancreatic pseudocyst.
Young Jun KIM ; Mun Sup SIM ; Sang Eun MOON
Journal of the Korean Surgical Society 1992;43(6):820-828
No abstract available.
Pancreatic Pseudocyst*
5.Surgical treatment of delta phalanx.
Moon Sang CHUNG ; Jun O YOON ; Bong Soon CHANG ; Young Wan MOON
The Journal of the Korean Orthopaedic Association 1991;26(3):832-840
No abstract available.
6.The clinical aspects of pulmonary tuberculosis patient failed in retreatment.
Young Jae IM ; Ju Young SONG ; Jae Man JEONG ; Young Jun KIM ; Moon Shik KIM
Tuberculosis and Respiratory Diseases 1993;40(4):404-410
No abstract available.
Humans
;
Retreatment*
;
Tuberculosis, Pulmonary*
7.Clinical application of 24 hours 67Ga scan.
Jun Woo LEE ; Young Jun LEE ; Tae Yong MOON ; Byung Soo KIM
Journal of the Korean Radiological Society 1991;27(6):895-900
No abstract available.
8.The Effect of the Extents of Pleural Thickening in Tuberculous Pleurisy on the Impairment of Pulmonary Function.
Young Kyoung LEE ; Moon Jun NA ; Bo Ra YUN ; Won Young LEE
Tuberculosis and Respiratory Diseases 2001;51(3):240-247
BACKGROUND: Tuberculous pleurisy treatment improve symptoms such as fever, chest pain, cough, and prevents the progression to active pulmonary tuberculosis and the development of residual pleural thickening that decrease diaphragm and rib cage movement. This study investigated how the degree of residual pleural thidkening affects the pulmonary function. METHODS: Fifty seven patients who were initially diagnosed as having tuberculous pleurisy, were treated with anti-tuberculous medication for 6 months and had residual pleural thickening between May 1998 and January 2000 at the Eulji university hospital were reviewed. A chest X-ray and pulmonary function test(PFT, Sensormedics 2200) were perfored. The predicted value (%) of the forced vital capacity(FVC), forced inspiratory vital capacity(FIVC) and total lung capacity(TLC) were measured. The residual pleural thickening was defined the average of the summation in the lateral chest at the level of the imaginary line intersecting from the cardiophrenic angle to the diaphragmatic dome and the lowest part of the costophrenic angle between them. The results were sorted into three grades according to pleural thickness; <2mm(grade I), 2~10mm(grade II), 10mm(grade III). RESULTS: 1. FVC(% pred) and FIVC(% pred) were statistically different between grade I and III, and II and III. However, there was no difference between the TLC(% pred) between each of the groups. 2. The pleural thickness that cause restrictive dysfunction(FVC<80%) and a statisticall difference, is 3 mm. CONCLUSION: The larger the extent of the residual pleural thickness after antituberculous medication, the greater the reduction in the FVC, FIVC, TLC. A pleural thickness of 3 mm is recommended as a guideline for diagnosing a restrictive pulmonary dysfunction.
Chest Pain
;
Cough
;
Diaphragm
;
Fever
;
Humans
;
Lung
;
Respiratory Function Tests
;
Ribs
;
Thorax
;
Tuberculosis, Pleural*
;
Tuberculosis, Pulmonary
9.A clinical effect of retreatment by prothionamide, cycloserine, para-aminosalicylic acid, streptomycin(kanamycin or tuberactinomyc-in) on pulmonary tuberculosis.
Cheol Shick SHIN ; Young Jae IM ; Young Jun KIM ; Seok Shin KOH ; Moon Shik KIM
Tuberculosis and Respiratory Diseases 1992;39(2):167-171
No abstract available.
Aminosalicylic Acid*
;
Cycloserine*
;
Prothionamide*
;
Retreatment*
;
Tuberculosis, Pulmonary*
10.A Case of Mucoepidermoid Carcinoma in Pulmonary Tuberculosis Patient.
Jae Man JEONG ; Ju Young SONG ; Jae Rack HONG ; Young Jun KIM ; Moon Shik KIM
Tuberculosis and Respiratory Diseases 1994;41(4):429-434
Mucoepidermoid carcinoma of lung are rare carcinoma arising from the submucosal glands tissue of the proximal tracheobronchial tree. The carcinoma can be divided into low grade and high grade varienties. The most important factors in the prognosis include histological grading and the ability to achieve a complete surgical resection. We experienced a case of high grade mucoepidermoid carcinoma in pulmonary tuberculosis patient of 67 years old male who has been suffered from left chest pain for several weeks. He was not treated and died seventeen months later.
Carcinoma, Mucoepidermoid*
;
Chest Pain
;
Humans
;
Lung
;
Male
;
Prognosis
;
Trees
;
Tuberculosis, Pulmonary*